83 related articles for article (PubMed ID: 1342235)
1. Acute effect of the somatostatin analogue SMS-201995 on plasma glucose and triglycerides in insulin-dependent diabetic patients.
Malerbi DA; de-Camargo JW; Cesar FP; Wajchenberg BL
Braz J Med Biol Res; 1992; 25(6):593-600. PubMed ID: 1342235
[TBL] [Abstract][Full Text] [Related]
2. Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus.
Spinas GA; Bock A; Keller U
Diabetes Care; 1985; 8(5):429-35. PubMed ID: 2865093
[TBL] [Abstract][Full Text] [Related]
3. [Effect of octreotide on blood glucose levels in poorly compensated insulin-dependent diabetics on insulin treatment].
Lunetta M; Di Mauro M; Le Moli R
Minerva Endocrinol; 1992; 17(1):7-12. PubMed ID: 1495454
[TBL] [Abstract][Full Text] [Related]
4. Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy.
Osei K; O'Dorisio TM; Malarkey WB; Craig EL; Cataland S
Diabetes; 1989 Jun; 38(6):704-9. PubMed ID: 2656340
[TBL] [Abstract][Full Text] [Related]
5. Improvement of diabetes after treatment with somatostatin analogue SMS 201-995 in an acromegalic patient.
Cantalamessa L; Catania A; Baldini M; Orsatti A
Horm Metab Res; 1986 Nov; 18(11):790-1. PubMed ID: 2878866
[TBL] [Abstract][Full Text] [Related]
6. Effects of a somatostatin derivative (SMS 201-995) on postprandial hyperglycemia in insulin-dependent diabetics studied by means of a closed-loop device.
Nosari I; Lepore G; Querci F; Maglio ML; Sileo F; Pagani G
J Endocrinol Invest; 1989 Jun; 12(6):413-7. PubMed ID: 2671112
[TBL] [Abstract][Full Text] [Related]
7. The effects of SMS 201-995 (sandostatin) on metabolic profiles in insulin-dependent diabetes mellitus.
Grossman LD; Shumak SL; George SR; Singer W; Zinman B
J Clin Endocrinol Metab; 1989 Jan; 68(1):63-7. PubMed ID: 2642488
[TBL] [Abstract][Full Text] [Related]
8. The effects of the somatostatin analogue SMS 201-995 on carbohydrate homeostasis of insulin-dependent diabetics as assessed by the artificial endocrine pancreas.
Hadjidakis DJ; Halvatsiotis PG; Ioannou YJ; Mavrokefalos PJ; Raptis SA
Diabetes Res Clin Pract; 1988 Jul; 5(2):91-8. PubMed ID: 2901329
[TBL] [Abstract][Full Text] [Related]
9. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus.
Kirkegaard C; Nørgaard K; Snorgaard O; Bek T; Larsen M; Lund-Andersen H
Acta Endocrinol (Copenh); 1990 Jun; 122(6):766-72. PubMed ID: 2197845
[TBL] [Abstract][Full Text] [Related]
10. Continuous subcutaneous octreotide infusion: dose-response relationships between metabolic effects and octreotide clearance in patients with insulin-dependent (type 1) diabetes.
Osei K; O'Dorisio TM; Malarkey WB; Cataland S
J Lab Clin Med; 1991 Jul; 118(1):56-64. PubMed ID: 2066644
[TBL] [Abstract][Full Text] [Related]
11. Effect of twice daily subcutaneous administration of a long-acting somatostatin analog on 24-hour plasma glucose profiles in patients with insulin-dependent diabetes mellitus.
Dimitriadis G; Gerich J
Horm Metab Res; 1985 Oct; 17(10):510-1. PubMed ID: 2866155
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
13. Effects of the somatostatin analogue SMS 201-995 (sandostatin) on mouth-to-caecum transit time and absorption of fat and carbohydrates in normal man.
Møller N; Petrany G; Cassidy D; Sheldon WL; Johnston DG; Laker MF
Clin Sci (Lond); 1988 Oct; 75(4):345-50. PubMed ID: 3058374
[TBL] [Abstract][Full Text] [Related]
14. Effect of a long-acting somatostatin derivative SMS 201-995 (sandostatin) on glucose homeostasis in type I diabetes mellitus.
Navascues I; Gil J; Pascau C; Senén D; del Pozo E; Serrano-Ríos M
Horm Res; 1988; 29(2-3):92-4. PubMed ID: 2900205
[TBL] [Abstract][Full Text] [Related]
15. Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin dependent diabetes mellitus.
Williams G; Füessl HS; Burrin JM; Chilvers E; Bloom SR
Horm Metab Res; 1988 Mar; 20(3):168-70. PubMed ID: 2898427
[TBL] [Abstract][Full Text] [Related]
16. Effects of a long-acting somatostatin analogue on postprandial hyperglycemia in insulin-dependent diabetes mellitus.
Dimitriadis G; Tessari P; Gerich J
Metabolism; 1983 Oct; 32(10):987-92. PubMed ID: 6136893
[TBL] [Abstract][Full Text] [Related]
17. Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal profiles in insulin-treated type II diabetic patients.
Candrina R; Giustina G
J Endocrinol Invest; 1988; 11(7):501-7. PubMed ID: 3049768
[TBL] [Abstract][Full Text] [Related]
18. Lack of pharmacological effect of subcutaneous octreotide in an insulin-dependent diabetic patient: reversal after mixing with aprotinin.
Lunetta M; Di Mauro M; Le Moli R
J Endocrinol Invest; 1997 Jun; 20(6):331-4. PubMed ID: 9294779
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas.
Rios MS; Navascues I; Saban J; Ordoñez A; Sevilla F; Del Pozo E
J Clin Endocrinol Metab; 1986 Nov; 63(5):1071-4. PubMed ID: 2876005
[TBL] [Abstract][Full Text] [Related]
20. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients.
Lamberts SW; Oosterom R; Neufeld M; del Pozo E
J Clin Endocrinol Metab; 1985 Jun; 60(6):1161-5. PubMed ID: 2860119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
